Agile Therapeutics, Inc. :AGRX-US: Earnings Analysis: Q2, 2016 By the Numbers : October 11, 2016

Agile Therapeutics, Inc. reports financial results for the quarter ended June 30, 2016.


  • Summary numbers: Revenues of USD 0 million, Net Earnings of USD -8.42 million.
  • The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless.
  • AGRX-US‘s earnings and EBITDA are both negative which suggest that P/E or Price/EBITDA are not meaningful to make this analysis between operating advantage (ROE) and growth expectations (as suggested by P/E or P/EBITDA).
  • Cash and Cash equivalents were up this period to 59.22 million compared to 46.41 million in the same period last year.
  • With debt at a relatively low 8.89% of its enterprise value compared to an overall benchmark of 25% (Note: The peer median is currently 8.89%), and relatively tight interest coverage level of -14.98x, AGRX-US would have a hard time raising much additional debt. Thus, the company is classified as having Limited Flexibility when it comes to raising more debt.
  • Of the 9 chosen peers for the company, only 7 of the stocks have an outstanding debt balance. Companies with no debt include TXMD-US and ATRS-US.
  • Net income of -8.42 million this period compared to a net income of -7.32 million last period. This is a growth of -15.03% over the previous period. In comparison, the peer group grew at -3.83%

Access our Ratings and Scores for Agile Therapeutics, Inc.

Earnings Growth YOY %

Access our Ratings and Scores for Agile Therapeutics, Inc.

Company Profile

Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company, which focused on the development and commercialization of new prescription contraceptive products. Its product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company products include Twirla AG200, AG200-ER and AG200-SP. Agile Therapeutics was founded on December 22, 1997 and is headquartered in Princeton, NJ.

CapitalCube does not own any shares in the stocks mentioned and focuses solely on providing unique fundamental research and analysis on approximately 50,000 stocks and ETFs globally. Try any of our analysis, screener or portfolio premium services free for 7 days. To get a quick preview of our services, check out our free quick summary analysis of AGRX-US.